UC Davis

Surgery

Title

Natural Killer and Cytotoxic T Cell Immune Infiltrates are Associated with Superior Outcomes in Soft Tissue Sarcomas

Permalink

https://escholarship.org/uc/item/76s1w86d

Authors

Cruz, Sylvia M Judge, Sean J Darrow, Morgan A et al.

Publication Date

2022

Data Availability

The data associated with this publication are not available for this reason: N/A



Natural Killer and Cytotoxic T Cell Immune Infiltrates are Associated with Superior Outcomes in Soft Tissue Sarcomas



Sylvia M Cruz¹, Sean J Judge, MD¹, Morgan A Darrow, MD², Cordelia Dunai, PhD³, Shuai Chen, PhD⁴, Steven W Thorpe, MD⁵, Robert J Canter, MD¹

¹Division of Surgical Oncology, Department of Surgery, University of California Davis School of Medicine; ²Pathology and Laboratory Medicine, University of California Davis School of Medicine; ³Dermatology, University of California Davis School of Medicine; ⁴Public Health Sciences, University of California Davis School of Medicine

Background

Immunotherapy has been a game changer in cancer treatment; however, there is currently a lack of effective immunotherapies for soft tissue sarcomas (STS). Although the majority of current cancer immunotherapies focus on amplifying the anti-tumor properties of Tcells, natural killer (NK) cells have been shown to be promising targets due to their innate cytotoxic characteristics, their ability to target cells without prior sensitization, and their ability to respond to diverse stimuli. Tumor infiltrating lymphocytes (TILs) have been shown to predict survival in STS, but the contribution of specific lymphocyte subsets such as NK and memory T cells to STS outcomes is undefined^{1,2}.

Objectives

To characterize the extent of NK and T cell infiltration in STS and to determine the correlation of these cytotoxic immune cells to patient outcomes

Methods

Archived tumor tissue from 90 STS patients collected from 2008-2020 was evaluated. Tissue microarrays (TMAs) were constructed, and immunohistochemical (IHC) analyses were performed by an STS pathologist for CD3, CD8, CD45RO, NKp46, TIGIT, and MHC-I. TIL scores of H&E slides were calculated. Metastasis-free survival (MFS) and overall survival (OS) were analyzed by Kaplan-Meier method.

Results

Table 1: Patient and clinical characteristics

	N = 90
Age (years)	62 (22 – 89)
Male	58%
Tumor size (cm)	13.2 (1.8 – 36)
Tumor site	
Extremity	58%
Retroperitoneal	23%
Trunk	16%
Tumor histology	
Liposarcoma	29%
Myxofibrosarcoma	23%
Pleomorphic sarcoma	20%
Leiomyosarcoma	7%
Other	21%
Survival	
Distant recurrence	53%
Died	28%
Median follow-up (months)	46 (0 – 143)
Median MFS (months)	25
Median OS (months)	91

Figure 3: Correlation of lymphocytic infiltrates with immunomodulatory markers MHC-I and TIGIT. MHC-I – stimulatory for T cells and inhibitory for NK cells; TIGIT – immune cell exhaustion marker

Figure 1: Representative IHC staining




Figure 2: Patient overall survival and metastasisfree survival.





Figure 4: Cytotoxic lymphocyte subsets and overall survival. A) CD8 is a marker for cytotoxic T cells. B) NKp46 is a marker for NK cells



Conclusions

- We confirmed a positive correlation between TILs and improved outcomes in STS, including cytotoxic cells.
- We noted a trend of higher NKp46 scores to correlate with superior overall survival.
- Immune infiltrates, including NK cells, are prognostic in STS.
- These results may be relevant in other checkpoint resistance tumors, like pancreatic and colorectal cancer.

Future Directions

Further characterization of immune infiltrate in STS and other cancers is needed. Potential clinical translation includes:

- Biomarkers of prognosis
- Immune targeting

Acknowledgements

Robert Canter MD, Morgan Darrow MD, Richard Bold MD, Sean Judge MD, UC Davis Cancer Center Biorepository

Project funded by the UC Davis
Comprehensive Cancer Center and UC
Davis Medical Student Research
Fellowship

References

- I. Judge SJ, Darrow MA, Thorpe SW, et al. Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. *Journal for ImmunoTherapy of Cancer* 2020;**8:**e001355. doi:10.1136/jitc-2020-001355
- 2. Myers, J.A., Miller, J.S. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18, 85–100 (2021). https://doi.org/10.1038/s41571-020-0426-7